YU42792A - Stabilizovan čvrst dozni oblik sa kontrolisanim oslobadjanjem koji ima prevlaku izvedenu od vodene disperzije etilceluloze i postupak za njegovo dobijanje - Google Patents

Stabilizovan čvrst dozni oblik sa kontrolisanim oslobadjanjem koji ima prevlaku izvedenu od vodene disperzije etilceluloze i postupak za njegovo dobijanje

Info

Publication number
YU42792A
YU42792A YU42792A YU42792A YU42792A YU 42792 A YU42792 A YU 42792A YU 42792 A YU42792 A YU 42792A YU 42792 A YU42792 A YU 42792A YU 42792 A YU42792 A YU 42792A
Authority
YU
Yugoslavia
Prior art keywords
dosage form
aqueous dispersion
controlled release
ethycellulose
obtaining
Prior art date
Application number
YU42792A
Other languages
English (en)
Other versions
YU48345B (sh
Inventor
B. Oshlack
M. Chasin
F. Pedi
Original Assignee
Euroceltique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25214195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU42792(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euroceltique S.A. filed Critical Euroceltique S.A.
Publication of YU42792A publication Critical patent/YU42792A/sh
Publication of YU48345B publication Critical patent/YU48345B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Paints Or Removers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Adhesive Tapes (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Coating Of Shaped Articles Made Of Macromolecular Substances (AREA)
  • Laminated Bodies (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Push-Button Switches (AREA)
  • Reinforced Plastic Materials (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Colloid Chemistry (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

STABILIZOVAN ČVRST DOZNI OBLIK SA KONTROLISANIM OSLOBADJANJEM KOJI IMA PREVLAKU IZVEDENU OD VODENE DISPERZIJE ETILCELULOZE I POSTUPAK ZA NJEGOVO DOBIJANJE, pronalazak se odnosi Stabilizovan čvrsti dozni oblik sa kontrolisanim oslobadjanjem koji ima prevlaku izvedenu od vodene disperzije etilceluloze i na postupak za njegovo dobijanje, a koji se sastoji u prevlačenju supstrata koji uključuje terapeutski aktivno sredstvo vodenom disperzijom etilceluloze i zatim vulkanizaciji prevučenog supstrata na temperaturi i pri relativnoj vlažnosti koji su podignuti na podesan nivo iznad običnih uslova, dok dozni oblik ne dostigne stabilizovan profil rastvaranja na koji se u suštini ne utiče izlaganjem uslovima za skladištenje na povišenoj temperaturi i/ili pri povišenoj relativnoj vlažnosti.
YU42792A 1991-12-24 1992-04-22 Stabilizovan čvrsti dozni oblik sa kontrolisanim oslobadjanjem koji ima prevlaku izvedenu od vodene disperzije etilceluloze i postupak za njegovo dobijanje YU48345B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/814,111 US5273760A (en) 1991-12-24 1991-12-24 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer

Publications (2)

Publication Number Publication Date
YU42792A true YU42792A (sh) 1994-09-09
YU48345B YU48345B (sh) 1998-07-10

Family

ID=25214195

Family Applications (1)

Application Number Title Priority Date Filing Date
YU42792A YU48345B (sh) 1991-12-24 1992-04-22 Stabilizovan čvrsti dozni oblik sa kontrolisanim oslobadjanjem koji ima prevlaku izvedenu od vodene disperzije etilceluloze i postupak za njegovo dobijanje

Country Status (24)

Country Link
US (1) US5273760A (sh)
EP (1) EP0548448B1 (sh)
JP (1) JP3061474B2 (sh)
KR (1) KR100252188B1 (sh)
AT (1) ATE196079T1 (sh)
AU (1) AU652871B2 (sh)
BR (1) BR9202982A (sh)
CA (1) CA2061824C (sh)
DE (1) DE69231415T2 (sh)
DK (1) DK0548448T3 (sh)
EG (1) EG20083A (sh)
ES (1) ES2152221T3 (sh)
FI (1) FI921548A (sh)
GR (1) GR3034951T3 (sh)
HK (1) HK1005686A1 (sh)
IE (1) IE920795A1 (sh)
IL (1) IL101080A (sh)
MX (1) MX9200932A (sh)
NO (1) NO312577B1 (sh)
NZ (1) NZ241660A (sh)
PT (1) PT548448E (sh)
SG (1) SG44703A1 (sh)
YU (1) YU48345B (sh)
ZA (1) ZA921366B (sh)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) † 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
GB2284760B (en) * 1993-11-23 1998-06-24 Euro Celtique Sa A method of preparing pharmaceutical compositions by melt pelletisation
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
JP3623805B2 (ja) * 1992-02-20 2005-02-23 ユーロセルテイツク・エス・アー ヒドロモルホンスフェロイド調整放出製剤
US5626872A (en) * 1992-06-16 1997-05-06 Roemmers S.A.I.C.F. Pharmaceutical soft capsules containing lysine clonixinate and a process for their preparation
JPH0687684A (ja) * 1992-08-13 1994-03-29 Chisso Corp 被覆粒状肥料
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
SE9301057L (sv) † 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
EP0647448A1 (en) * 1993-10-07 1995-04-12 Euroceltique S.A. Orally administrable opioid formulations having extended duration of effect
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5871776A (en) * 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5637319A (en) * 1995-03-01 1997-06-10 Takada; Kanji Controlled-release preparations
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
WO1998001117A1 (en) 1996-07-08 1998-01-15 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
ES2263211T3 (es) 1997-07-02 2006-12-01 Euro-Celtique S.A. Formulaciones de tramadol de liberacion sostenida estabilizada.
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US20020188037A1 (en) * 1999-04-15 2002-12-12 Chudzik Stephen J. Method and system for providing bioactive agent release coating
US6126967A (en) * 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
DE19901686A1 (de) 1999-01-18 2000-07-20 Gruenenthal Gmbh Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung
US6800329B2 (en) * 1999-02-12 2004-10-05 Lts Lohmann Therapie-Systeme Ag Method for producing film-type dosage
IN191239B (sh) 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
JP3893058B2 (ja) * 1999-09-30 2007-03-14 ペンウェスト ファーマシューティカルズ カンパニー 高度に可溶性の薬物のための徐放性マトリックス系
ES2374717T3 (es) 1999-10-29 2012-02-21 Euro-Celtique S.A. Formulaciones de hidrocodona de liberación controlada.
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
GEP20053614B (en) 2000-02-08 2005-09-26 Euro Celtique Sa Compositions for Oral Administration Containing Opioid Agonist
EP1935421A1 (en) 2000-02-08 2008-06-25 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
WO2002036099A1 (en) * 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
US7052706B2 (en) * 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
WO2003007802A2 (en) 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
AU2002323032B2 (en) 2001-08-06 2005-02-24 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003020242A1 (en) * 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
WO2003074474A2 (en) 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
CA2708900C (en) * 2002-04-05 2019-06-04 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
JP2006500377A (ja) 2002-06-21 2006-01-05 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 改善された溶解性を有する医薬組成物
CN1674873A (zh) 2002-08-15 2005-09-28 欧罗赛铁克股份有限公司 药物组合物
US20060052432A1 (en) * 2002-09-20 2006-03-09 Julius Remenar Pharmaceutical compositions with improved dissolution
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
US20060148877A1 (en) * 2002-11-26 2006-07-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
WO2004054542A2 (en) 2002-12-13 2004-07-01 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP2298303A1 (en) 2003-09-25 2011-03-23 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
ATE544447T1 (de) 2003-09-26 2012-02-15 Alza Corp Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
AU2004275835B2 (en) * 2003-09-26 2011-06-23 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
JP5610663B2 (ja) * 2003-11-04 2014-10-22 スパーナス ファーマシューティカルズ インコーポレイテッド トロスピウムの１日１回剤形
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
WO2005060968A1 (en) 2003-12-11 2005-07-07 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
TWI483944B (zh) 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
WO2005123039A1 (en) 2004-06-12 2005-12-29 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
KR20080046751A (ko) * 2004-09-01 2008-05-27 유로-셀띠끄 소시에떼 아노님 용량 비례적 정상 상태 Ｃａｖｅ및 ＡＵＣ를 갖고, 용량비례적 단일 용량 Ｃｍａｘ보다 작은 오피오이드성 제형
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
KR20090029856A (ko) * 2005-01-28 2009-03-23 유로-셀띠끄 소시에떼 아노님 알코올 저항성 제형
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
CA2616416A1 (en) 2005-09-09 2007-05-03 Labopharm, Inc. Trazodone composition for once a day adminisitiation
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
WO2007092718A2 (en) * 2006-02-07 2007-08-16 Fmc Corporation Coating process to produce controlled release coatings
KR101495146B1 (ko) * 2006-03-16 2015-02-24 트리스 파마 인코포레이티드 약물 - 이온교환 수지 복합체를 함유하는 변형 방출 제제
EP1839649A1 (en) * 2006-03-31 2007-10-03 LEK Pharmaceuticals D.D. Coated formulations for tolterodine
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
EP2526932B1 (en) 2006-06-19 2017-06-07 Alpharma Pharmaceuticals LLC Pharmaceutical composition
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
BRPI0815387B8 (pt) * 2007-08-13 2021-05-25 Abuse Deterrent Pharmaceutical Llc composição farmacêutica, método para fazer uma composição farmacêutica e uso da composição farmacêutica
PT2057984E (pt) 2007-11-09 2010-03-10 Acino Pharma Ag Comprimidos retard com hidromorfona
WO2009075782A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2328539B1 (en) 2008-09-25 2018-04-18 ISP Investments LLC Smooth, high solids tablet coating composition
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
PT2405915T (pt) 2009-03-10 2019-01-29 Euro Celtique Sa Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
BR112012022797A2 (pt) * 2010-03-09 2018-02-20 Alkermes Pharma Ireland Ltd composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
EP2568977A1 (en) 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended- release oral dosage forms
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
ES2444591T3 (es) 2010-10-28 2014-02-25 Acino Pharma Ag Medicamento con el principio activo hidromorfona con estabilidad al almacenamiento mejorada
EP2651399A2 (en) 2010-12-13 2013-10-23 Purdue Pharma LP Controlled release dosage forms
MY166034A (en) 2010-12-22 2018-05-21 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
US9233073B2 (en) 2010-12-23 2016-01-12 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
EP2606880A1 (en) * 2011-12-23 2013-06-26 LEK Pharmaceuticals d.d. Coating process with aqueous latex coating
CA2868413C (en) 2012-04-17 2021-07-20 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
EP2844296B1 (en) * 2012-05-02 2019-03-13 Capsugel Belgium NV Aqueous dispersions of hydroxypropyl methylcellulose acetate succinate (hpmcas)
NZ715111A (en) 2012-07-16 2016-12-23 Rhodes Technologies Process for improved opioid synthesis
BR112015000944A2 (pt) 2012-07-16 2019-10-15 Rhodes Tech processo para síntese melhorada de opioide
ES2851175T3 (es) 2013-02-05 2021-09-03 Purdue Pharma Lp Formulaciones farmacéuticas resistentes a manipulación
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
WO2014144975A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP3024461B1 (en) 2013-07-23 2020-05-13 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
AU2014298257B2 (en) 2013-08-02 2016-11-10 Macfarlan Smith Limited Process for the preparation of oxymorphone
US20160256399A1 (en) 2013-11-04 2016-09-08 Capsugel Belgium Nv Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole
AU2015207733A1 (en) 2014-01-15 2016-07-14 Rhodes Technologies Process for improved oxycodone synthesis
ES2672795T3 (es) 2014-01-15 2018-06-18 Rhodes Technologies Proceso para la síntesis mejorada de oximorfona
BR112016020738B1 (pt) 2014-03-11 2023-04-11 Dupont Nutrition Usa, Inc Composição de liberação controlada e método
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
EP2937096B1 (en) 2014-04-23 2019-08-21 Julius-Maximilians-Universität Würzburg Peptides derived from RS1 which down-regulate glucose absorption after a glucose rich meal and increase insulin sensitivity
CA2947515A1 (en) * 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
WO2015166473A1 (en) 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
MA40448A (fr) 2014-07-30 2016-02-04 Sun Pharmaceutical Ind Ltd Emballage à double chambre
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
MA41124A (fr) * 2014-12-05 2017-10-10 Sun Pharmaceutical Ind Ltd Compositions en suspension à libération prolongée à rétention gastrique
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
ES2925951T3 (es) 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
CN108836948B (zh) * 2018-06-11 2024-04-12 宁波西敦医药包衣科技有限公司 一种利用包衣技术实现营养素可控制释放的产品
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60166608A (ja) * 1984-02-08 1985-08-29 Japan Atom Energy Res Inst サンドイツチ構造をもつ徐放性複合体およびその製造方法
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
GB2170104A (en) * 1985-01-30 1986-07-30 Warner Lambert Co Coated pharmaceutical dosage forms
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5042842A (en) * 1990-06-26 1991-08-27 Avery International Corporation High security label

Also Published As

Publication number Publication date
BR9202982A (pt) 1993-06-29
NZ241660A (en) 1993-05-26
CA2061824C (en) 1999-04-06
NO312577B1 (no) 2002-06-03
IL101080A (en) 1996-12-05
EG20083A (en) 1997-05-31
EP0548448A1 (en) 1993-06-30
AU3002492A (en) 1993-07-01
JP3061474B2 (ja) 2000-07-10
HK1005686A1 (en) 1999-01-22
IL101080A0 (en) 1992-11-15
DE69231415T2 (de) 2001-03-29
DK0548448T3 (da) 2001-01-22
KR100252188B1 (ko) 2000-05-01
ZA921366B (en) 1992-12-30
MX9200932A (es) 1993-06-01
NO925016L (no) 1993-06-25
ATE196079T1 (de) 2000-09-15
FI921548A (fi) 1993-06-25
US5273760A (en) 1993-12-28
CA2061824A1 (en) 1993-06-25
GR3034951T3 (en) 2001-02-28
SG44703A1 (en) 1997-12-19
DE69231415D1 (de) 2000-10-12
NO925016D0 (no) 1992-12-23
PT548448E (pt) 2001-03-30
FI921548A0 (fi) 1992-04-08
EP0548448B1 (en) 2000-09-06
IE920795A1 (en) 1993-06-30
YU48345B (sh) 1998-07-10
KR930012006A (ko) 1993-07-20
ES2152221T3 (es) 2001-02-01
AU652871B2 (en) 1994-09-08
JPH07165609A (ja) 1995-06-27

Similar Documents

Publication Publication Date Title
YU42792A (sh) Stabilizovan čvrst dozni oblik sa kontrolisanim oslobadjanjem koji ima prevlaku izvedenu od vodene disperzije etilceluloze i postupak za njegovo dobijanje
EG20307A (en) A method for obtaining a stabilized controlled release formulations having acrylic polymer coating
CA2077572A1 (en) Method of and apparatus for stabilizing shapes of objects, such as optical elements, as well as exposure apparatus using same and method of manufacturing semiconductr devices
US3365296A (en) Light-sensitive ultraviolet absorbing compounds and diazotype materials containing the same
JPS5754905A (en) Manufacture of color filter
US3386826A (en) Process for producing improved diazotype elements
GB1257442A (sh)
GB1509314A (en) Radiation-sensitive resist-forming composition
JPS52153951A (en) Acetic acid ester derivatives, their preparation, and insecticide miticides containing same
JPS57154239A (en) Photosensitive recording material
JPS5772136A (en) Formation of image
JPS54138366A (en) Manufacture for color receiving tube
IT1109089B (it) Procedimento di stampa fotografica su oggetti ceramici
FR2432726A1 (fr) Procede perfectionne de decoration sur ceramique et ceramiques comportant une telle decoration